Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Ikaros degradation by mezigdomide reduces T-cell dysfunction (by regulating TIGIT, an important T cell exhaustion gene) and improves the efficacy of anti-myeloma T-cell therapies, including CAR T.”
Title: Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies
Authors: Lucia Y. Chen, Adolfo Aleman, Marta Larrayoz, Hsiling Chiu, Junfei Zhao, Oliver Van Oekelen, Geoffrey Kelly, Seunghee Kim-Schulze, Alessandro Lagana, Sundar Jagannath, Tracy T. Chow, Teresa Lozano, Juan J. Lasarte, Joseph C. Hamley, Warren Baker, Benjamin L. Ebert, Udo Oppermann, Michael D. Amatangelo, Anita Krithivas Gandhi, Patrick Ryan Hagner, Jose A. Martínez-Climent, Sarah Gooding, Thomas A. Milne, Samir Parekh
You can read the Full Article in Blood.
You can find other articles featuring Robert Orlowski on OncoDaily.
